Job Trends
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
A United Kingdom watchdog organization has accused Pfizer and Flynn Pharma of violating antitrust rules and overcharging that country’s National Health Services for anti-epilepsy treatments.
Gilead Sciences’ Kite Pharma has entered into a collaboration and licensing agreement with biotech startup Appia Bio, which will focus on the joint research and development of allogeneic cell therapies for cancer.
Under the terms of the agreement, Bayer is paying $1.5 billion upfront and up to $500 million in various milestone payments.
With the acquisition of the Roche stake, SoftBank has become one of the company’s biggest stakeholders.
The new $550 million site in N.C. follows the advanced packaging plant in Ohio that will significantly expand the company’s manufacturing capacity in the U.S.
Eli Lilly and Company is in the news with positive Olumiant data in COVID-19, a drop in COVID-19 product sales for the quarter and a protest of one of their ads. Here’s a look.
North Carolina’s biopharma business continues to expand at a rapid pace. Not only has the state’s hub in the Research Triangle Park continued to prosper, but companies are expanding in other areas across the state as well.
Seventeen years after buying global rights, AstraZeneca is finally announcing a win for the lupus community with an FDA approval for Saphnelo.
With the Alzheimer’s Association International Conference conference last week, there were plenty of clinical trial news and updates. Here’s a look.
As Gilead gets ready to open its doors to its new operations site in North Carolina, the company reported its product sales for the second quarter increased 21% year-over-year primarily driven by Veklury.